Peanut Allergy Study for Children Age 6-17
Stanford University
Logo Image
"Help us evaluate if a study drug reduces peanut allergy symptoms."
Age: 6-17
Healthy Volunteers: No
Keywords: Peanut, Clinical Trial, Allergy, Peanut Allergy, Allergy Trial, monotherapy
Type: Phase II
15 Participants
We are trying to find out if a biologic drug (dupilumab) can help reduce allergic reactions to peanut exposure in peanut-allergic children. This is a phase II study that will last about nine months.

The Sean N. Parker Center for Allergy and Asthma Research at Stanford University aims to discover underlying immune mechanisms behind allergies to develop a lasting cure.
This study requires
  • Participants will have to be seen in clinic every 2 weeks for approximately 9 months.
  • Participants will eat very small amounts of peanut in clinic to test their level of reaction (food challenge).
  • This study does not involve eating any peanut (also called oral immunotherapy, OIT) outside of our clinic. Participants will receive dupilumab as an injection under the skin.

The safety and efficacy of dupilumab for this use has not been evaluated by any regulatory authority.

Who can participate
  • Children age 6-17 with a diagnosed peanut allergy can participate.

We will go over all eligibility criteria during a screening visit.

Benefits and risks of participating
Your participation may contribute to advancing the knowledge of allergies and the human immune system.
Sean N. Parker Center for Allergy & Asthma Research at Stanford University
2500 Grant Road
El Camino Hospital, Tower 4C Room 4C347
Mountain View, CA 94040
MacKenzie Cox

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview